ATTAIN-MAINTAIN tested oral orforglipron after tirzepatide or semaglutide. More prior weight loss was retained than with placebo; continued injections were not compared.
Browsing: GLP-1 Receptor Agonists
Clinical trial summaries for GLP-1 receptor agonists, including cardiovascular outcomes, glycaemic control, obesity, kidney outcomes, tolerability, and practice implications.
ATTAIN-1 found that oral orforglipron 36 mg reduced body weight by 11.2% versus 2.1% with placebo over 72 weeks in adults with obesity without diabetes.
In STEP UP, semaglutide 7.2 mg reduced body weight by 18.7% versus 3.9% with placebo and outperformed semaglutide 2.4 mg in adults with obesity without diabetes.
In REDEFINE 1, once-weekly cagrilintide-semaglutide produced 20.4% mean weight loss at 68 weeks versus 3.0% with placebo in adults with overweight or obesity without diabetes.
In REDEFINE 2, CagriSema reduced weight by 13.7% versus 3.4% with placebo at 68 weeks, and 73.5% achieved HbA1c <=6.5% in adults with type 2 diabetes.
In high-risk type 2 diabetes, once-daily oral semaglutide 14 mg cut major adverse cardiovascular events versus placebo in the SOUL trial, with no kidney benefit shown. PICO summary and expert commentary.
An EXSCEL post hoc simulation and mediation analysis showing conventional risk-factor changes explain only a modest share of once-weekly exenatide’s cardiovascular effects. PICO summary and expert commentary.
An RCT finds adding a ketogenic diet to dulaglutide improves glucose, lipids, and insulin resistance in type 2 diabetes. PICO summary and clinical expert commentary.
A Lancet phase 2 RCT finds once-weekly semaglutide 2.4 mg reduces heavy drinking days in alcohol use disorder with obesity. PICO summary and expert commentary for clinicians.
The SCALE trial established liraglutide 3.0 mg as the first GLP-1 receptor agonist approved for chronic weight management, demonstrating a mean weight reduction of 8.0% versus 2.6% with placebo and a 79% reduction in progression from prediabetes to type 2 diabetes in a 160-week extension analysis, setting the clinical and regulatory template for GLP-1 receptor agonist obesity pharmacotherapy.